The strong Phase 2 data for SPY001 in ulcerative colitis suggests a high probability of success in later-stage trials. Investors should monitor upcoming data readouts for SPY002 and SPY003 in mid-2026 and Q3 2026, respectively. The company's stock may experience positive momentum in the near term.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $63.27entry
- T+1 · 7mo ago +1.17%α −0.04% · $64.01
- T+5 · 7mo ago +15.99%α +12.70% · $73.39
- T+20 · 6mo ago +20.80%α +13.07% · $76.43
- T+60 · 4mo ago +50.78%α +41.86% · $95.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics announced positive Phase 2 topline data for SPY001 in ulcerative colitis, showing statistically significant efficacy and a favorable safety profile. The company also announced the closure of Part A enrollment and the opening of Part B for additional cohorts, indicating continued clinical progress.
Key Facts
- SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points in the Robarts Histopathology Index (RHI) score (p<0.0001)
- Key secondary endpoints included a 40% clinical remission rate and 51% endoscopic improvement rate
- SPY001 was well tolerated with a safety profile consistent with the 47 class, with no drug-related serious adverse events
- Recruitment for Part A of the SKYLINE trial is closed, and enrollment is now open for Part B
Financial Impact
The positive topline data significantly improves the drug's development prospects, potentially increasing its market value by hundreds of millions of dollars
Risk Factors
- Potential delays in regulatory approval
- Competition from other ulcerative colitis treatments
- Safety concerns in later-stage trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-024831 |
| Exhibit: exhibit991-8xkdatarelease.htm | 0001628280-26-024831 |
| Document: 0001628280-26-024831-index-headers.html | 0001628280-26-024831 |
| Document: 0001628280-26-024831-index.html | 0001628280-26-024831 |
| Document: 0001628280-26-024831.txt | 0001628280-26-024831 |
Track record
36 reports on SYRE
7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers